Kristopher A. Lofgren

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Kristopher A. Lofgren, Kristopher A Lofgren, Kristopher Andrew Lofgren, Kristopher Lofgren
Publication record
38 papers · 548 citations · H-index 9

PAPERS

Grb7 is dispensable for Erbb2-driven mouse mammary tumorigenesis
20250 citationsauthor #1
Abstract A061: Grb7 is dispensible for normal development and ERBB2-driven mammary tumorigenesis, but maternal Grb7 deletion causes lactational insufficiency
20240 citationsauthor #1
Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids
20242 citationsauthor #2
Grb7 knockout mice develop normally but litters born to knockout females fail to thrive
20233 citationsauthor #1
Mammary-specific ectopic expression of mutant human GATA3 did not potentiate medroxyprogesterone acetate-driven mouse mammary tumorigenesis
20230 citationsauthor #1
Abstract B133: Anti-tumor efficacy of GMF-1A3-MMAE, an antibody drug conjugate targeting cell surface cleaved Amphiregulin in endocrine-resistant breast cancer
20230 citationsauthor #1
Abstract 562: Anti-tumor efficacy of GMF-1A3, an MMAE-based antibody drug conjugate targeting cell surface cleaved Amphiregulin in breast cancer
20230 citationsauthor #1
Abstract P3-07-02: Anti-tumor efficacy of GMF-1A3, an MMAE-based antibody drug conjugate targeting cell surface cleaved Amphiregulin in breast cancer
20230 citationsauthor #1
Abstract 331: Pre-clinical evaluation in endocrine resistant breast cancer of a novel antibody-drug conjugate targeting cell surface cleaved Amphiregulin
20220 citationsauthor #1
Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate
20224 citationsauthor #1
Anti-tumor efficacy of an MMAE conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer
202110 citationsauthor #1
Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer
20215 citationsauthor #1
Abstract P184: Anti-tumor efficacy of an MMAE conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer
20210 citationsauthor #1
Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
202013 citationsauthor #5
Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice
20194 citationsauthor #3
SAT-331 Elucidating the Role of Breast Cancer Specific GATA3 Mutation in Estrogen Receptor Positive Breast Cancer
20190 citationsauthor #1
Abstract 1317: Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations
20192 citationsauthor #6
Abstract 1822: Emergence of MET D1228N mutation as a resistance mechanism following an exceptional response to crizotinib in a MET-amplified triple-negative breast cancer patient
20181 citationsauthor #4
Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells
201831 citationsauthor #2
Abstract 2522: Luminal epithelial cell expression of amphiregulin is required for mammary gland development and facilitates mutant p53-driven tumorigenesis
20180 citationsauthor #1
Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors.
20180 citationsauthor #2
Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor.
20176 citationsauthor #4
Abstract 2827: Establishing a mouse model to investigate GRB7-mediated signaling in development and triple-negative breast cancer
20170 citationsauthor #1
Abstract 3399: Genomic analysis of melanoma evolution following a 30 year disease-free interval
20171 citationsauthor #2
Genomic analysis of melanoma evolution following a 30‐year disease‐free interval
20176 citationsauthor #2
An instructive ductal microenvironment is key for efficient in vivo modeling of estrogen receptor positive breast cancer
20161 citationsauthor #1
Abstract 723: GRB7 promotes doxorubicin resistance in triple-negative breast cancer cells via multiple signaling pathways
20150 citationsauthor #1
Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer.
201545 citationsauthor #3
Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.
201360 citationsauthor #5
Erratum: Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression (Cancer Research (2013) 73 (5810-20))
20130 citationsauthor #5
Tumor and Stem Cell Biology Breast Tumor Kinase ( Brk / PTK 6 ) Is a Mediator of Hypoxia-Associated Breast Cancer Progression
20130 citationsauthor #5
Control of lung vascular permeability and endotoxin-induced pulmonary oedema by changes in extracellular matrix mechanics
2013124 citationsauthor #7
Mechanisms of HGF/Met Signaling to Brk and Sam68 in Breast Cancer Progression
201152 citationsauthor #2
Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK
201137 citationsauthor #1
Modeling Brk/PTK6 Expression in the Mammary Epithelium
20100 citationsauthor #1
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
2007144 citationsauthor #3
TITLE: Investigation of the Role of Breast Tumor Kinase (Brk) in ERK5 and p38-Mediated Breast Cancer Cell
20070 citationsauthor #2
Investigation of the Role of Breast Tumor Kinase (Brk) in ERK5 and p38-Mediated Breast Cancer Cell
20070 citationsauthor #1

TIMELINE

2007 144 citations

2010 0 citations

2011 89 citations

2013 184 citations

2015 45 citations

2016 1 citations

2017 13 citations

2018 32 citations

2019 6 citations

2020 13 citations

2021 15 citations

2022 4 citations

2023 3 citations

2024 2 citations

2025 0 citations

Kristopher A. Lofgren

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT